Position in VRDN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$75,945,788
-$44,884,116 QoQ
Shares Held
3,882,709
0.0% QoQ
Ownership
3.77%
of shares outstanding
% of Portfolio
2.83%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2020
22 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in VRDN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Venrock Adviser, LLC holds $2,679,121,844 across 33 Biotechnology names. VRDN ranks #10 (2.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
8,493,321 | $714,882,828 | |
| 2 | ERAS |
Erasca, Inc.
|
16,382,812 | $265,073,898 | |
| 3 | ORKA |
Oruka Therapeutics, Inc.
|
4,148,428 | $203,480,393 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
3,685,448 | $185,893,997 | |
| 5 | KALV |
KalVista Pharmaceuticals, Inc.
|
6,474,485 | $130,331,383 | |
| 6 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
1,180,000 | $99,025,600 | |
| 7 | DMRA |
Damora Therapeutics, Inc.
|
3,603,595 | $93,333,110 | |
| 8 | OCUL |
Ocular Therapeutix, Inc
|
10,346,926 | $87,638,463 |
All Filings in VRDN
Export CSV
22 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $75,945,788 | 3,882,709 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $120,829,904 | 3,882,709 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $83,788,860 | 3,882,709 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $54,280,271 | 3,882,709 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $52,338,917 | 3,882,709 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $74,431,531 | 3,882,709 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $88,331,629 | 3,882,709 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $50,513,549 | 3,882,671 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $67,985,569 | 3,882,671 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $84,563,528 | 3,882,623 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $47,287,421 | 3,082,622 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $73,335,577 | 3,082,622 | Shares | Sole | 2023-08-11 | |
| 2023-03-31 | $68,684,565 | 2,699,865 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $78,863,056 | 2,699,865 | Shares | Sole | 2023-05-15 | |
| 2022-09-30 | $43,692,617 | 2,130,308 | Shares | Sole | 2023-05-15 | |
| 2022-06-30 | $21,438,272 | 1,852,919 | Shares | Sole | 2023-05-15 | |
| 2022-03-31 | $34,260,472 | 1,852,919 | Shares | Sole | 2022-05-16 | |
| 2021-12-31 | $36,632,208 | 1,852,919 | Shares | Sole | 2022-02-14 | |
| 2021-09-30 | $320,692 | 19,495 | Shares | Sole | 2021-11-15 | |
| 2021-06-30 | $356,563 | 19,495 | Shares | Sole | 2021-08-13 | |
| 2021-03-31 | $325,761 | 19,495 | Shares | Sole | 2021-05-14 | |
| 2020-12-31 | $320,692 | 19,495 | Shares | Sole | 2021-02-12 | |
| No filing history on record for this holder in this stock. | ||||||